Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and its senior executives for potential violations of federal securities laws, following disappointing results from its Phase 3 VELA trials for sonelokimab [1][2][3]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases, particularly through its investigational therapeutic sonelokimab [3]. Clinical Trials and Data - The company claimed that its "strong clinical data" from the Phase 2 MIRA trial indicated higher clinical responses for patients and a competitive edge for sonelokimab over traditional monoclonal antibody treatments [4]. - However, the lawsuit alleges that the clinical data and the Nanobody structure of sonelokimab did not provide a superior clinical benefit compared to competitors, raising doubts about the drug's regulatory approval and commercial viability [5]. Stock Performance - Following the announcement of disappointing results from the VELA Phase 3 trials on September 28, 2025, MoonLake's stock price plummeted by $55.75 per share, nearly 90%, from $61.99 on September 26, 2025, to $6.24 on September 29, 2025 [6].

Group 1 - The article highlights the upcoming deadline of December 15, 2025, for investors to file a lead plaintiff motion in a case related to MoonLake Immunotherapeutics (NASDAQ: MLTX) [1] - The class period for the case is defined as between March 10, 2024, and September 29, 2025, during which investors purchased common stock of MoonLake [1] - Investors who suffered losses in MoonLake Immunotherapeutics are encouraged to contact the Law Offices of Howard G. Smith for assistance [1]

Core Viewpoint - A class action securities lawsuit has been filed against MoonLake Immunotherapeutics, alleging securities fraud affecting investors between March 10, 2024, and September 29, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements regarding MoonLake's drug candidate SLK, asserting that it shares molecular targets with BIMZELX and that SLK's unique Nanobody structure does not provide superior clinical benefits [2]. - Allegations include that SLK's supposed increased tissue penetration does not translate to clinical efficacy, and thus the defendants lacked a reasonable basis for their positive claims about SLK's superiority over monoclonal antibodies [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until December 15, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States, with over 70 employees dedicated to serving clients [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of MoonLake Immunotherapeutics during the specified Class Period of the upcoming lead plaintiff deadline on December 15, 2025 [1]. Group 1: Class Action Details - Investors who bought MoonLake common stock between March 10, 2024, and September 29, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6]. - The lawsuit claims that the defendants made false or misleading statements regarding the efficacy of their product compared to traditional monoclonal antibodies, leading to investor damages when the truth was revealed [5]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - A class action lawsuit has been filed against MoonLake Immunotherapeutics (MLTX) for securities fraud, following disappointing Phase 3 results for its drug candidate sonelokimab (SLK) [1][3]. Summary by Sections Lawsuit Announcement - The Law Offices of Frank R. Cruz announced a class action lawsuit on behalf of shareholders who purchased MLTX common stock between March 10, 2024, and September 29, 2025, with a deadline of December 15, 2025, for filing a lead plaintiff motion [1]. Disappointing Drug Results - On September 28, 2025, MoonLake announced that SLK failed to match the efficacy of its competitor's drug, BIMZELX, despite prior claims of its superiority [3]. - The company had promoted SLK's nanobody structure as superior but allegedly did not disclose that it targeted the same molecules as BIMZELX and lacked proven advantages [3]. Stock Price Impact - Following the announcement of the disappointing results, MoonLake's stock plummeted by $55.74, or 89.9%, closing at $6.24 per share on September 29, 2025, significantly harming investors [4]. Allegations in the Lawsuit - The lawsuit alleges that during the Class Period, the defendants made materially false and misleading statements and failed to disclose adverse facts about the company's business and prospects, including: 1. SLK and BIMZELX share the same molecular targets [5]. 2. SLK's nanobody structure would not provide superior clinical benefits over BIMZELX [5]. 3. The supposed increased tissue penetration of SLK would not translate to clinical efficacy [5]. 4. Positive statements about the company's business were materially misleading and lacked a reasonable basis [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against MoonLake (NASDAQ: MLTX) due to allegations of violations of federal securities laws related to misleading statements about its product SLK compared to BIMZELX [1][3]. Group 1: Allegations Against MoonLake - The complaint alleges that MoonLake and its executives made false and misleading statements regarding the efficacy and clinical benefits of SLK compared to traditional monoclonal antibodies [3]. - Specific claims include that SLK and BIMZELX share the same molecular targets, and that SLK's unique structure does not provide superior clinical benefits or efficacy [3]. - Following the announcement of Phase 3 VELA program results, which showed SLK's failure to demonstrate competitive efficacy, MoonLake's stock price dropped by $55.75 per share, or 89.9%, closing at $6.24 [4]. Group 2: Legal Proceedings and Investor Actions - Investors who purchased MoonLake securities between March 10, 2024, and September 29, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal rights and options [1]. - The deadline for seeking the role of lead plaintiff in the federal securities class action against MoonLake is December 15, 2025 [1]. - Any member of the putative class can move the court to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [5].

Core Viewpoint - A class action securities lawsuit has been filed against MoonLake Immunotherapeutics, alleging securities fraud that affected investors between March 10, 2024, and September 29, 2025 [1][2]. Group 1: Lawsuit Details - The complaint claims that the defendants made false statements regarding the company's drug candidate SLK, asserting that it shares molecular targets with BIMZELX and that SLK's unique Nanobody structure does not provide superior clinical benefits [2]. - It is alleged that the supposed increased tissue penetration of SLK does not translate to clinical efficacy, indicating a lack of reasonable basis for the positive statements made about SLK's superiority over traditional monoclonal antibodies [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until December 15, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, emphasizing that there is no cost or obligation to participate [3]. Group 3: Legal Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and its senior executives for potential violations of federal securities laws, following disappointing results from its Phase 3 clinical trials for sonelokimab [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, under the case name Peters v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08612 [2]. - Investors have until December 15, 2025, to request to be appointed to lead the case [2]. Group 2: Company Background - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases [3]. - The company conducted Phase 3 VELA trials for sonelokimab, aimed at treating moderate to severe hidradenitis suppurativa [3]. Group 3: Clinical Data and Allegations - MoonLake claimed that its "strong clinical data" from the Phase 2 MIRA trial indicated higher clinical responses and differentiation from competitors [4]. - Allegations suggest that the clinical data and Nanobody structure did not provide a superior clinical benefit, raising doubts about the drug's regulatory approval and commercial viability [5]. Group 4: Stock Performance - Following the announcement of disappointing results from the VELA Phase 3 trials on September 28, 2025, MoonLake's stock price plummeted nearly 90%, from $61.99 per share to $6.24 per share [6].

Core Viewpoint - A class action lawsuit has been filed against MoonLake Immunotherapeutics, alleging violations of federal securities laws due to false and misleading statements regarding the company's business and prospects [1][6]. Company Overview - MoonLake Immunotherapeutics is a Swiss clinical-stage biotechnology company focused on inflammatory diseases driven by interleukin-17 (IL-17), particularly in dermatology and rheumatology [4]. - The company's sole drug candidate, sonelokimab (SLK), is primarily developed for hidradenitis suppurativa (HS) and also targets psoriatic arthritis, psoriasis, and axial spondyloarthritis [4]. Clinical Development - MoonLake began its Phase 2b MIRA trial of sonelokimab in May 2022, reporting positive top-line results in June 2023, achieving its primary HiSCR75 endpoint [5]. - Follow-up data in October 2023 indicated further improvement with continued treatment, and both the FDA and EMA endorsed the proposed Phase 3 program, which began patient screening in May 2024 [5]. Allegations and Stock Impact - The lawsuit claims that throughout the class period, the defendants made false statements regarding the efficacy of SLK compared to traditional monoclonal antibodies, including claims about molecular targets and clinical benefits [6]. - On September 28, 2025, MoonLake announced that SLK failed to demonstrate competitive efficacy relative to the traditional monoclonal structure BIMZELX, leading to a significant stock price drop of $55.75 per share, or 89.9%, closing at $6.24 on September 29, 2025 [7].

Core Viewpoint - MoonLake Immunotherapeutics, a Swiss clinical-stage biotechnology company, is facing a class action lawsuit for allegedly misleading investors about the efficacy of its drug candidate SLK, which is aimed at treating inflammatory diseases driven by interleukin-17 (IL-17) [1][3]. Company Overview - MoonLake is focused on developing treatments for inflammatory diseases, particularly in dermatology and rheumatology, utilizing a unique Nanobody structure [1]. Legal Allegations - The lawsuit claims that during the class period, MoonLake failed to disclose critical information regarding the efficacy of SLK compared to BIMZELX, an FDA-approved drug. Key points include: - Both SLK and BIMZELX target the same inflammatory cytokines IL-17A and IL-17F [3]. - The distinct Nanobody structure of SLK does not provide a clinical benefit over the traditional monoclonal antibody structure of BIMZELX [3]. - Claims of increased tissue penetration by SLK do not translate to improved clinical efficacy [3]. - The company lacked a reasonable basis for its positive statements regarding SLK's superiority [3]. Stock Performance Impact - Following the announcement of disappointing week-16 results from the Phase 3 VELA program on September 28, 2025, MoonLake's stock price plummeted by $55.75 per share, or 89.9%, closing at $6.24 on September 29, 2025 [4]. Class Action Participation - Shareholders may be eligible to participate in the class action against MoonLake. Those wishing to serve as lead plaintiffs must submit their papers by December 15, 2025 [5]. Legal Representation - Robbins LLP is leading the class action, specializing in shareholder rights litigation and has been active in helping shareholders recover losses and improve corporate governance since 2002 [6].